An clinical analysis of multiple myeloma in 120 newly diagnosed patients
10.3760/cma.j.issn.1008-6315.2010.11.020
- VernacularTitle:新诊断多发性骨髓瘤患者120例临床分析
- Author:
Jun LI
;
Shulian YANG
;
Maosheng WANG
;
Erying HAN
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Chemotherapy
- From:
Clinical Medicine of China
2010;26(11):1178-1180
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical features in multiple myeloma(MM)patients, and the summaries the treatment effect of different therapies. Methods The clinical initial symptoms, laboratory data,clinical efficacy of treatment with MP, M2, VAD, BD,T hal + DEX and other chemotherapy in 120 patients newly diagnosed with multiple myeloma were retrospectively analyzed. Results Among 120 MM cases,the incidence peak was situated in 40 - 60 years age group, the mean age at oneset was 54 years, which indicated that the onset age were getting younger in China. Bone pain, anemia, infection were the most common initial symptoms of MM. In terms of clinical efficacy:①Significant difference between MP and VAD programs(χ2 = 10. 626,P ＜0. 05＝,but no significant difference between MP and M2 programs(χ2 = 2. 439, P ＞ 0. 05), MP and Thal + DEX programs(χ2 = 5. 870, P ＞0. 05. ②Significant difference between M2 and VAD programs(χ2 = 8. 307, P ＜ 0. 05＝; No significant difference between M2 and Thal + DEX programs(χ2 = 2. 592, P ＞ 0. 05). ③ No significant difference between VAD and Thal +DEX programs(χ2 =0. 916,P＞ 0. 05). ④BD program is the most efficient program,but this discovery need further confirmation because of the small number of cases observed. Conclusions At present, chemotherapy is the main treatment for MM, most scheme like MP, M2, VAD, BD, etc. , have certain effect depend on different patient groups but remain improving. The choice of appropriate chemotherapy and autologous or allogeneic hematopoietic stem cell transplantation will help to improve the prognosis of the disease.
